Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACME LaboratoriesDHA:ACMELAB -0.84%85 ROC (Joel Greenblatt) % is 12.13% as of Mar. 2026, which is 6% above its 10-year median of 11.46. GuruFocus rates DHA:ACMELAB with a GF Score™ of 85/100 and a GF Value™ of BDT126.19 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 981 Drug Manufacturers companies, ACME Laboratories ranks worse than 53.01% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. ACME Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 12.13%.
The historical rank and industry rank for ACME Laboratories's ROC (Joel Greenblatt) % or its related term are showing as below:
DHA:ACMELAB'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 9.65 Med: 11.46 Max: 13.2
Current: 9.65
During the past 9 years, ACME Laboratories's highest ROC (Joel Greenblatt) % was 13.20%. The lowest was 9.65%. And the median was 11.46%.
DHA:ACMELAB's ROC (Joel Greenblatt) % is ranked worse than 53.01% of 981
companies
in the Drug Manufacturers industry
Industry Median: 11.46
vs DHA:ACMELAB: 9.65
ACME Laboratories's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -0.50% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
ACME Laboratories ROC (Joel Greenblatt) % Related Terms
ACME Laboratories ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 12.13% mean?
ACME Laboratories (DHA:ACMELAB) has a ROC (Joel Greenblatt) % of 12.13% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on ACME Laboratories and its competitors. This is near median its historical median of 11.46. Over the past decade, ACME Laboratories' ROC (Joel Greenblatt) % has ranged from 9.65 to 13.20. According to the industry distribution chart, ACME Laboratories ranks #520 out of 981 companies in the Drug Manufacturers industry, placing it in the top 53%.
Is ACME Laboratories' ROC (Joel Greenblatt) % too high?
ACME Laboratories' current ROC (Joel Greenblatt) % of 12.13% is near median its 10-year median of 11.46. Over the past 10 years, this metric has ranged from a low of 9.65 to a high of 13.20. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.46. ACME Laboratories' value of 12.13% is 5.8% above this industry median. Based on the distribution chart, ACME Laboratories ranks #520 out of 981 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, ACME Laboratories has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #520 out of 981 companies for ROC (Joel Greenblatt) %. This places ACME Laboratories in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.46. ACME Laboratories' value of 12.13% is 5.8% above this benchmark. Historically, ACME Laboratories' own ROC (Joel Greenblatt) % has ranged from 9.65 to 13.20 over the past decade. While the company's 10-year median is 11.46 vs. the industry median of 11.46, ACME Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current ROC (Joel Greenblatt) % of 12.13% is 5.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current ROC (Joel Greenblatt) % is 12.13%, which is near median its own 10-year median of 11.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT126.19, compared to a current price of BDT82.80 — trading 34.4% below its estimated fair value. The current ROC (Joel Greenblatt) % is 12.13%, which is near median its 10-year median of 11.46 and 5.8% above the Drug Manufacturers industry median of 11.46. ACME Laboratories' overall GF Score™ is 85/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current ROC (Joel Greenblatt) % is 12.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT82.80 is trading 34.4% below its estimated GF Value™ of BDT126.19.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
ROC (Joel Greenblatt) %: 12.13% (near median its 10-year median of 11.46)
GF Value™: BDT126.19 vs. price of BDT82.80 (34.4% below fair value)
Industry Position: 5.8% above the Drug Manufacturers median (#520 of 981)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
85GF Score
Get the complete analysis for DHA:ACMELAB
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
